-
公开(公告)号：US08951525B2
公开(公告)日：2015-02-10
申请号：US13803887
申请日：2013-03-14
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
IPC: A61K39/395 , C07K16/46 , C07K16/36 , C07K16/28 , A61K39/00
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
-
Patent Agency Ranking
公开(公告)号：US20230094867A1
公开(公告)日：2023-03-30
申请号：US17825244
申请日：2022-05-26
Applicant: Janssen Biotech, Inc.
Inventor： Katharine D. Grugan , Christian R. Martinez , Nan Wei , Hong Mimi Zhou
Abstract: In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a CD9B441 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include CD9B441.
-
公开(公告)号：US20200024360A1
公开(公告)日：2020-01-23
申请号：US16418328
申请日：2019-05-21
Applicant: Janssen Biotech, Inc.
Inventor： Glenn Mark Anderson , Tammy Bush , Rosa Maria Fernandes Cardoso , Ellen Chi , Judith Ann Connor , Thai Quang Dinh , Derrick Lemon Domingo , John Michael Jones , Colleen Kane , Bethany Kay Mattson , Theresa Marie McDevitt , Jill Marie Mooney , Richard Stephen Tawadros , Hong Mimi Zhou
Abstract: The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
公开(公告)号：US08999333B2
公开(公告)日：2015-04-07
申请号：US14230128
申请日：2014-03-31
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos Almagro , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
Abstract translation: 本发明涉及能够预防组织因子（凝血因子F3）信号传导但不干扰因子VII结合或FX与组织因子结合并且不延长凝血时间的抗体的人源化形式。 本发明的抗体可用于治疗相关细胞表达组织因子和组织因子信号传导的病症，例如肿瘤进展。
-
公开(公告)号：US11746157B2
公开(公告)日：2023-09-05
申请号：US16418328
申请日：2019-05-21
Applicant: Janssen Biotech, Inc.
Inventor： Glenn Mark Anderson , Tammy Bush , Rosa Maria Fernandes Cardoso , Ellen Chi , Judith Ann Connor , Thai Quang Dinh , Derrick Lemon Domingo , John Michael Jones , Colleen Kane , Bethany Kay Mattson , Theresa Marie McDevitt , Jill Marie Mooney , Richard Stephen Tawadros , Hong Mimi Zhou
CPC classification number: C07K16/3069 , C07K16/2809 , C07K2317/21 , C07K2317/31 , C07K2317/515 , C07K2317/565 , C07K2317/76 , C07K2317/92
Abstract: The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
-
公开(公告)号：US20140234304A1
公开(公告)日：2014-08-21
申请号：US14230128
申请日：2014-03-31
Applicant: Janssen Biotech, Inc.
Inventor： Juan Carlos ALMAGRO , Glenn Mark Anderson , Ellen Chi , Christian Martinez , Gopalan Raghunathan , Ronald Swanson , Alexey Teplyakov , Kam-Fai Tse , Sheng-Jiun Wu , Hong Mimi Zhou
IPC: C07K16/40
CPC classification number: C07K16/40 , A61K2039/505 , C07K16/28 , C07K16/36 , C07K16/464 , C07K2317/24 , C07K2317/34 , C07K2317/41 , C07K2317/524 , C07K2317/55 , C07K2317/565 , C07K2317/72 , C07K2317/732 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The invention relates to a humanized form of an antibody capable of preventing tissue factor (coagulation factor F3) signaling but which does not interfere with Factor VII binding or FX binding to tissue factor and does not prolong coagulation time. The antibody of the invention is useful in treating conditions, such as tumor progression, in which the associated cells express tissue factor and tissue factor signaling occurs.
Abstract translation: 本发明涉及能够预防组织因子（凝血因子F3）信号传导但不干扰因子VII结合或FX与组织因子结合并且不延长凝血时间的抗体的人源化形式。 本发明的抗体可用于治疗相关细胞表达组织因子和组织因子信号传导的病症，例如肿瘤进展。
-
-
-
-
-
Search Results
6
records
(took 0.016 seconds)
